James A. Windelborn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James A. Windelborn has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gordon S. Mitchell
Breathing Research and Therapeutics Center University of Florida Gainesville Florida USA
6 shared publications C.H. Guenther
Department of Comparative Biosciences, University of Wisconsin, Madison, WI 53706, USA
3 shared publications- Stéphane Vinit
END-ICAP, UVSQ, Inserm, Université Paris-Saclay, 78000 Versailles, France
3 shared publications - Adrianne G. Huxtable
University of Oregon
1 shared publication Emani R. Silva
Department of Biology Washington College Chestertown MD USA
1 shared publication- Eric V Schmidt
Departments of Neurology and Physiology & Biophysics, Neuromuscular Biology & Disease Group, Boston University School of Medicine, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 10 August 2020
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 3 (3) , 256-263
A comparison between chemical and gas hypoxia as models of global ischemia in zebrafish (Danio rerio)
Background: Zebrafish models for neurovascular diseases offer new methods for elucidation of molecular pathways to tissue damage. External fertilization and high fecundity provide opportunities for transgenics and other forms of genetic manipulation that are more accessible than offered by mammalian models of disease. Furthermore, behavioral analyses of zebrafish allow for connection of molecular pathways to organismal outputs such as locomotion, learning, and memory. Unfortunately, a zebrafish model of hypoxia‐ischemia has been slow to catch on, possibly due to hypoxia exposure protocols that are challenging to reproduce and result in high mortality.Methods: In this study, we have introduced a predictable and simple method of hypoxia induction, the addition of sodium sulfite to aquarium water. The effects of this treatment on zebrafish locomotion were compared to those of zebrafish exposed to hypoxia induced by nitrogen gas bubbling, a method used in previous reports.Results: We found that hypoxia induced by sodium sulfite significantly impaired locomotion in the hours following treatment, and its effects did not differ from those caused by nitrogen gas hypoxia.Conclusion: These results indicate that hypoxia by sodium sulfite represents an effective and easily reproducible method for the study of hypoxia‐ischemia in zebrafish.
- 10 August 2020
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 3 (3) , 256-263
Open AccessA comparison between chemical and gas hypoxia as models of global ischemia in zebrafish (Danio rerio)
Background: Zebrafish models for neurovascular diseases offer new methods for elucidation of molecular pathways to tissue damage. External fertilization and high fecundity provide opportunities for transgenics and other forms of genetic manipulation that are more accessible than offered by mammalian models of disease. Furthermore, behavioral analyses of zebrafish allow for connection of molecular pathways to organismal outputs such as locomotion, learning, and memory. Unfortunately, a zebrafish model of hypoxia‐ischemia has been slow to catch on, possibly due to hypoxia exposure protocols that are challenging to reproduce and result in high mortality.Methods: In this study, we have introduced a predictable and simple method of hypoxia induction, the addition of sodium sulfite to aquarium water. The effects of this treatment on zebrafish locomotion were compared to those of zebrafish exposed to hypoxia induced by nitrogen gas bubbling, a method used in previous reports.Results: We found that hypoxia induced by sodium sulfite significantly impaired locomotion in the hours following treatment, and its effects did not differ from those caused by nitrogen gas hypoxia.Conclusion: These results indicate that hypoxia by sodium sulfite represents an effective and easily reproducible method for the study of hypoxia‐ischemia in zebrafish.
- Open Access
- 6 December 2013
- Published by Springer Nature in Skeletal Muscle
- Vol. 3 (1) , 28
Immortalized myogenic cells from congenital muscular dystrophy type1A patients recapitulate aberrant caspase activation in pathogenesis: a new tool for MDC1A research
Congenital muscular dystrophy Type 1A (MDC1A) is a severe, recessive disease of childhood onset that is caused by mutations in the LAMA2 gene encoding laminin-α2. Studies with both mouse models and primary cultures of human MDC1A myogenic cells suggest that aberrant activation of cell death is a significant contributor to pathogenesis in laminin-α2-deficiency. To overcome the limited population doublings of primary cultures, we generated immortalized, clonal lines of human MDC1A myogenic cells via overexpression of both CDK4 and the telomerase catalytic component (human telomerase reverse transcriptase (hTERT)). The immortalized MDC1A myogenic cells proliferated indefinitely when cultured at low density in high serum growth medium, but retained the capacity to form multinucleate myotubes and express muscle-specific proteins when switched to low serum medium. When cultured in the absence of laminin, myotubes formed from immortalized MDC1A myoblasts, but not those formed from immortalized healthy or disease control human myoblasts, showed significantly increased activation of caspase-3. This pattern of aberrant caspase-3 activation in the immortalized cultures was similar to that found previously in primary MDC1A cultures and laminin-α2-deficient mice. Immortalized MDC1A myogenic cells provide a new resource for studies of pathogenetic mechanisms and for screening possible therapeutic approaches in laminin-α2-deficiency.
- 6 December 2013
- Published by Springer Nature in Skeletal Muscle
- Vol. 3 (1) , 28
Open AccessImmortalized myogenic cells from congenital muscular dystrophy type1A patients recapitulate aberrant caspase activation in pathogenesis: a new tool for MDC1A research
Congenital muscular dystrophy Type 1A (MDC1A) is a severe, recessive disease of childhood onset that is caused by mutations in the LAMA2 gene encoding laminin-α2. Studies with both mouse models and primary cultures of human MDC1A myogenic cells suggest that aberrant activation of cell death is a significant contributor to pathogenesis in laminin-α2-deficiency. To overcome the limited population doublings of primary cultures, we generated immortalized, clonal lines of human MDC1A myogenic cells via overexpression of both CDK4 and the telomerase catalytic component (human telomerase reverse transcriptase (hTERT)). The immortalized MDC1A myogenic cells proliferated indefinitely when cultured at low density in high serum growth medium, but retained the capacity to form multinucleate myotubes and express muscle-specific proteins when switched to low serum medium. When cultured in the absence of laminin, myotubes formed from immortalized MDC1A myoblasts, but not those formed from immortalized healthy or disease control human myoblasts, showed significantly increased activation of caspase-3. This pattern of aberrant caspase-3 activation in the immortalized cultures was similar to that found previously in primary MDC1A cultures and laminin-α2-deficient mice. Immortalized MDC1A myogenic cells provide a new resource for studies of pathogenetic mechanisms and for screening possible therapeutic approaches in laminin-α2-deficiency.
- 30 April 2012
- Published by Elsevier in Experimental Neurology
- Vol. 234 (2) , 513-520
Increased atypical PKC expression and activity in the phrenic motor nucleus following cervical spinal injury
- 30 April 2012
- Published by Elsevier in Experimental Neurology
- Vol. 234 (2) , 513-520
Increased atypical PKC expression and activity in the phrenic motor nucleus following cervical spinal injury
- 1 January 2012
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 180 (1) , 61-68
Glial activation in the spinal ventral horn caudal to cervical injury
- 1 January 2012
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 180 (1) , 61-68
Glial activation in the spinal ventral horn caudal to cervical injury
- 1 September 2011
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 178 (3) , 482-489
Systemic inflammation impairs respiratory chemoreflexes and plasticity
- 1 September 2011
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 178 (3) , 482-489
Systemic inflammation impairs respiratory chemoreflexes and plasticity
- 1 May 2011
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 176 (3) , 130-135
Lipopolysaccharide attenuates phrenic long-term facilitation following acute intermittent hypoxia
- 1 May 2011
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 176 (3) , 130-135
Lipopolysaccharide attenuates phrenic long-term facilitation following acute intermittent hypoxia
- 15 May 2010
- Published by Elsevier in Neuroscience
- Vol. 169 (2) , 787-793
Atypical protein kinase C expression in phrenic motor neurons of the rat
- 15 May 2010
- Published by Elsevier in Neuroscience
- Vol. 169 (2) , 787-793
Atypical protein kinase C expression in phrenic motor neurons of the rat
- 29 April 2009
- Published by Wiley in The Journal of Physiology
- Vol. 587 (9) , 1931-1942
NADPH oxidase activity is necessary for acute intermittent hypoxia‐induced phrenic long‐term facilitation
Phrenic long‐term facilitation (pLTF) following acute intermittent hypoxia (AIH) is a form of spinal, serotonin‐dependent synaptic plasticity that requires reactive oxygen species (ROS) formation. We tested the hypothesis that spinal NADPH oxidase activity is a necessary source of ROS for pLTF. Sixty minutes post‐AIH (three 5‐min episodes of 11% O2, 5 min intervals), integrated phrenic and hypoglossal (XII) nerve burst amplitudes were increased from baseline, indicative of phrenic and XII LTF. Intrathecal injections (∼C4) of apocynin or diphenyleneiodonium chloride (DPI), two structurally and functionally distinct inhibitors of the NADPH oxidase complex, attenuated phrenic, but not XII, LTF. Immunoblots from soluble (cytosolic) and particulate (membrane) fractions of ventral C4 spinal segments revealed predominantly membrane localization of the NADPH oxidase catalytic subunit, gp91phox, whereas membrane and cytosolic expression were both observed for the regulatory subunits, p47phox and RAC1. Immunohistochemical analysis of fixed tissues revealed these same subunits in presumptive phrenic motoneurons of the C4 ventral horn, but not in neighbouring astrocytes or microglia. Collectively, these data demonstrate that NADPH oxidase subunits localized within presumptive phrenic motoneurons are a major source of ROS necessary for AIH‐induced pLTF. Thus, NADPH oxidase activity is a key regulator of spinal synaptic plasticity, and may be a useful pharmaceutical target in developing therapeutic strategies for respiratory insufficiency in patients with, for example, cervical spinal injury.
- 29 April 2009
- Published by Wiley in The Journal of Physiology
- Vol. 587 (9) , 1931-1942
NADPH oxidase activity is necessary for acute intermittent hypoxia‐induced phrenic long‐term facilitation
Phrenic long‐term facilitation (pLTF) following acute intermittent hypoxia (AIH) is a form of spinal, serotonin‐dependent synaptic plasticity that requires reactive oxygen species (ROS) formation. We tested the hypothesis that spinal NADPH oxidase activity is a necessary source of ROS for pLTF. Sixty minutes post‐AIH (three 5‐min episodes of 11% O2, 5 min intervals), integrated phrenic and hypoglossal (XII) nerve burst amplitudes were increased from baseline, indicative of phrenic and XII LTF. Intrathecal injections (∼C4) of apocynin or diphenyleneiodonium chloride (DPI), two structurally and functionally distinct inhibitors of the NADPH oxidase complex, attenuated phrenic, but not XII, LTF. Immunoblots from soluble (cytosolic) and particulate (membrane) fractions of ventral C4 spinal segments revealed predominantly membrane localization of the NADPH oxidase catalytic subunit, gp91phox, whereas membrane and cytosolic expression were both observed for the regulatory subunits, p47phox and RAC1. Immunohistochemical analysis of fixed tissues revealed these same subunits in presumptive phrenic motoneurons of the C4 ventral horn, but not in neighbouring astrocytes or microglia. Collectively, these data demonstrate that NADPH oxidase subunits localized within presumptive phrenic motoneurons are a major source of ROS necessary for AIH‐induced pLTF. Thus, NADPH oxidase activity is a key regulator of spinal synaptic plasticity, and may be a useful pharmaceutical target in developing therapeutic strategies for respiratory insufficiency in patients with, for example, cervical spinal injury.
- Open Access
- 20 March 2008
- Published by Wiley in Journal of Neurochemistry
- Vol. 106 (1) , 56-69
Lysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA‐mediated calcium influx, arachidonic acid metabolism, and free radical production
NMDA‐mediated calcium entry and reactive oxygen species (ROS) production are well‐recognized perpetrators of ischemic neuronal damage. The current studies show that these events lead to the release of the protein hydrolase, cathepsin B, from lysosomes 2 h following 5‐min oxygen–glucose deprivation in the rat hippocampal slice. This release reflects a lysosomal membrane permeabilization (LMP) and was measured as the appearance of diffuse immunolabeled cathepsin B in the cytosol of CA1 pyramidal neurons. Necrotic neuronal damage begins after the release of cathepsins and is prevented by inhibitors of either cathepsin B or D indicating that the release of cathepsins is an important mediator of severe damage. There was an increase in superoxide levels, measured by dihydroethidium fluorescence, at the same time as LMP and reducing ROS levels with antioxidants, Trolox or N‐tert‐butyl‐α‐phenyl nitrone, blocked LMP. Both LMP and ROS production were blocked by an NMDA channel blocker (MK‐801) and by inhibitors of mitogen‐activated protein kinase kinase (U0126), calcium‐dependent/independent phospholipases A2 (methyl arachidonyl fluorophosphonate) but not calcium‐independent phospholipases A2 (bromoenol lactone) and cyclooxygenase‐2 (NS398). A cell‐permeant specific inhibitor of calpain (PD150606) prevented LMP, but not ROS production. It is concluded that LMP results in part from calcium‐initiated and extracellular signal‐regulated kinase‐initiated arachidonic acid metabolism, which produces free radicals; it also requires the action of calpain.
- 20 March 2008
- Published by Wiley in Journal of Neurochemistry
- Vol. 106 (1) , 56-69
Open AccessLysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA‐mediated calcium influx, arachidonic acid metabolism, and free radical production
NMDA‐mediated calcium entry and reactive oxygen species (ROS) production are well‐recognized perpetrators of ischemic neuronal damage. The current studies show that these events lead to the release of the protein hydrolase, cathepsin B, from lysosomes 2 h following 5‐min oxygen–glucose deprivation in the rat hippocampal slice. This release reflects a lysosomal membrane permeabilization (LMP) and was measured as the appearance of diffuse immunolabeled cathepsin B in the cytosol of CA1 pyramidal neurons. Necrotic neuronal damage begins after the release of cathepsins and is prevented by inhibitors of either cathepsin B or D indicating that the release of cathepsins is an important mediator of severe damage. There was an increase in superoxide levels, measured by dihydroethidium fluorescence, at the same time as LMP and reducing ROS levels with antioxidants, Trolox or N‐tert‐butyl‐α‐phenyl nitrone, blocked LMP. Both LMP and ROS production were blocked by an NMDA channel blocker (MK‐801) and by inhibitors of mitogen‐activated protein kinase kinase (U0126), calcium‐dependent/independent phospholipases A2 (methyl arachidonyl fluorophosphonate) but not calcium‐independent phospholipases A2 (bromoenol lactone) and cyclooxygenase‐2 (NS398). A cell‐permeant specific inhibitor of calpain (PD150606) prevented LMP, but not ROS production. It is concluded that LMP results in part from calcium‐initiated and extracellular signal‐regulated kinase‐initiated arachidonic acid metabolism, which produces free radicals; it also requires the action of calpain.